Whitepapers

Asthma management is supported by national guidelines that were initially created to emphasize the importance of treating the inflammatory nature of the disease to improve patient outcomes (NHLBI 1991). Today, FeNO (fractional exhaled nitric oxide) is a well-established, validated and specific biomarker for T2 driven airway inflammation in asthma following 20 years since the Nobel Prize was awarded in 1998 for understanding the importance of nitric oxide in the cardiovascular system.

By clicking Yes you will be taken to a third-party website or websites to which Circassia's Privacy Policy and other rules do not apply. Circassia is not responsible for the privacy policy of any third-party websites. You are solely responsible for interactions with such third-party website(s).